RecruitingNCT05024175

Long-term Follow-up of Subjects Treated With CAR T Cells


Sponsor

Marcela V. Maus, M.D.,Ph.D.

Enrollment

45 participants

Start Date

Aug 7, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.
  • Subjects meeting the following criteria are eligible for study participation:
  • Provision of voluntary written informed consent by subject
  • CAR T cells were administered in DF/HCC IRB corresponding main study

Exclusion Criteria2

  • Subjects meeting the following criterion are to be excluded from study participation:
  • \- Subject unable to comply with study requirements

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTDisease assessments

CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol

PROCEDURETumor Biopsy

Tumor Biopsy per protocol

DIAGNOSTIC_TESTBlood test

Blood Test per protocol


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05024175


Related Trials